Clinical trial
A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With…
NCT00131326 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00131326 |
|---|---|
| Title | A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Hip, Musculoskeletal Diseases |
| Intervention type | Device |
| Interventions | Synvisc (hylan G-F 20) |
| Start date | Nov 1, 2003 |
| Completion | Apr 1, 2006 |
| First posted | Aug 18, 2005 |
| Last update posted | Jul 31, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: